About US
Contact us
-
FDA approves Mylan's ANDA for generic Catapres-TTSMylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applicati2010/7/20
-
FDA warns public over safety of stolen Advair Diskus inhalersThe FDA is warning the public that certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers2010/7/19
-
Warner Chilcott announces new FDA PDUFA date of October 24, 2010 for ActonelWarner Chilcott plc (Nasdaq: WCRX) announced today that it has received a communication from the U.S. Food & Drug Administration (FDA) related to its next generation Actonel® product (risedron2010/7/19
-
SFDA releases the second issue of 2010 National Medical Device Quality AnnouncementThe State Food and Drug Administration (SFDA) released the second issue of 2010 National Medical Device Quality Announcement on July 8,2010 and publicized the quality sampling and testing results of s2010/7/19
-
Access announces agreement to develop oral formulation of proprietary injectable drugsAccess Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulat2010/7/16
-
American Heart Association comments on FDA advisory committee's rosiglitazone recommendationsAfter two days of hearings, an advisory committee to the U.S. Food and Drug Administration (FDA) recommended that the FDA allow the type 2 diabetes drug rosiglitazone (brand name, Avandia), to stay on2010/7/16
-
BASF increases prices for beta-carotene and its derivatesLudwigshafen , Germany – July 14, 2010 – BASF globally increases the prices for beta-carotene and its derivatives canthaxanthin and apocarotenal by 12% with immediate effect or as existing commitmen2010/7/15
-
OraVerse MAA accepted for review in five key European countriesSanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agenc2010/7/15
-
FDA opens two-day hearing to examine safety of diabetes drug AvandiaThe Fiscal Times: "There will be more at stake than just one drug's future when the Food and Drug Administration opens a two-day hearing Tuesday on the safety of the diabetes drug Avandia. The 30-memb2010/7/15
-
SPET-085 is effective in blocking critical enzyme that leads to BPH: StudyA new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract (SPE), SPET-085, is as effective as finasteride, the standard prescription drug therapy, i2010/7/14